225
Participants
Start Date
January 30, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Methadone
Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
Buprenorphine/naloxone
Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
XR-Naltrexone
Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
ACTIVE_NOT_RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Go Vap Clinic, Ho Chi Minh City
National Institute of Drug Abuse
FED
The Wistar Institute
OTHER
Institute of Applied Medicine and Epidemiology (IMEA)
UNKNOWN
Ho Chi Minh City CDC
OTHER_GOV
University of Pennsylvania
OTHER